Pooja Ghatalia, MD

Dr. Ghatalia
This physician is not currently rated. Why?

Why is this doctor not rated?


To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings
Request an Appointment

Clinical Locations

Assistant Professor, Department of Hematology/Oncology

Collaborating Member, Cancer Epigenetics



Treatment Focus

Chemotherapy, targeted chemotherapy, immunotherapy, hormone therapy, clinical trials for genitourinary malignancies

Research Program

Key Awards

2023 top doctors
Medical Oncology

Treatment Philosophy

I am a medical oncologist specializing in genitourinary cancers. Treating patients with cancer is a privilege for me as in the process of diagnosing and treating the illness I get to become the patient’s friend, resource and advocate. In the most difficult times of their life, each cancer patient and their family deserves the best possible care. I strive to provide excellent care by being a good listener, maintaining good communication with patients and my team, staying abreast with the rapidly evolving field of oncology and by providing individualized care to each patient.

I came to Fox Chase for my fellowship and stayed here because I loved the team and realized that at Fox Chase, each patient has the benefit of an interdisciplinary team working together to ensure the highest quality care. This team approach is crucial in determining and implementing the best treatment plan.

In my clinical practice I focus on the care of patients with kidney, prostate bladder, penile, adrenal and testicular cancer and I am proud to be part of a large multidisciplinary team of distinguished clinicians and researchers at Fox Chase.  Over the last decade, the number of treatment options for patients with advanced cancers has greatly expanded and at Fox Chase we can offer both the latest standard-of-care as well as new experimental approaches. My particular research interest is in developing biomarkers that can help understand the behavior of kidney cancers as well as clinical trial development for genitourinary cancers.

Educational Background

  • Fellowship, Hematology/Oncology, Temple University/ Fox Chase Cancer Center, Philadelphia, PA
  • Residency, Internal Medicine, University of Alabama at Birmingham, AL
  • MD, Albany Medical College (Cum Laude), Albany, NY, 2012


  • ABIM Board Certified in Hematology and Medical Oncology


  • American Society of Clinical Oncology
  • American Society of Hematology
  • American College of Physicians
  • Alpha Omega Alpha Honor medical society
  • American Medical Association

Honors & Awards

  • ASCO/AACR Molecular Biology in Clinical Oncology Workshop Selected Participant, Snowmass, CO, 2017
  • Kidney Cancer Association Young Investigator Award Research Grant, 2017
  • Trainees in Internal Medicine Mentored Experience in Research (TIME-R) award, 2014

Selected Publications

Ghatalia P., Handorf E.A., Geynisman D.M., Deng M., Zibelman M.R., Abbosh P., Anari F., Greenberg R.E., Viterbo R., Chen D., Smaldone M.C., Kutikov A., Uzzo R.G., The role of cytoreductive nephrectomy in metastatic renal cell carcinoma: A real world multi-institutional analysis. J Urol: 101097ju0000000000002495, 2022. https://www.ncbi.nlm.nih.gov/pubmed/35212574.

Ghatalia P.,Plimack E.R., Integration of immunotherapy into the treatment of advanced urothelial carcinoma. J Natl Compr Canc Netw. 18(3): 355-361, 2020. https://www.ncbi.nlm.nih.gov/pubmed/32135514.

Ghatalia P., Zibelman M., Geynisman D.M.,Plimack E.R., First-line immunotherapy in metastatic urothelial carcinoma. Eur Urol Focus. 6(1): 45-47, 2020. https://www.ncbi.nlm.nih.gov/pubmed/31103603.

Ghatalia P, Plimack ER. Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma. J Natl Compr Cance Network. 2020 18(3): 355-361. Cited in Pubmed: PMID 32135514

Nam H, Kundu A … Ghatalia P … Sudarshan S. PGC1α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression. Matrix Biology. Jan 2020 [Epub ahead of print] PMID: 31986037

Ghatalia P, Plimack E. Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer. Nature Med. 2019 25(11): 1650. Cited in Pubmed: PMID: 31686037

Winer A, Ghatalia P, Bubes N, Anari F, Varshavsky A, Kasireddy V, Liu Y, El-Deiry WS. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer. Oncologist. 2019 24(11): 1416-19. PMID: 31444293

Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai K, Devarajan K, Bae S, Naik G, Chan T, Uzzo R, Hakimi A, Sonpavde G, Plimack E. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma J Immunother Cancer. 2019 7(1): 139. Cited in Pubmed: PMID: 31138299

Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. First-line Immunotherapy in Metastatic Urothelial Carcinoma. Eur Urol Focus. 2019 6(1):45-47. Cited in Pubmed: PMID 21103603

Pabla S, Conroy JM … Ghatalia P… Morrison C. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019 7(1): 27. Cited in Pubmed: PMID 30709424... Expand

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...